PepGen Inc (NASDAQ:PEPG) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET

Company Participants

Noel Donnelly - Chief Financial Officer

James McArthur - President and Chief Executive Officer

Jaya Goyal - Executive Vice President, Research and Preclinical Development

Michelle Mellion - Senior Vice President and Head, Clinical Development

Conference Call Participants

Laura Chico - Wedbush

Operator

Good afternoon and welcome to the PepGen Conference Call to discuss PepGen’s Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, March 23, 2023.

I would now like to turn the conference call over to Noel Donnelly, Chief Financial Officer of PepGen. Noel, please go ahead.

Noel Donnelly

Thank you, Josh. Good afternoon, everyone and thank you for joining today’s call. Earlier today, we released our financials for the fourth quarter and full year 2022 and provide an update on recent corporate developments. Press release outlining our financial results is available at our website pepgen.com and our 10-K was filed with the SEC this afternoon.

Joining us on today’s call will be James McArthur, PhD, President and Chief Executive Officer; Jaya Goyal, PhD, Executive Vice President of Research and Preclinical Development; and Michelle Mellion, MD, Senior Vice President and Head of Clinical Development.

During this call, management will be making forward-looking statements. These forward-looking statements are based on the company’s current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the company described in the section titled Risk Factors in our current report on Form 10-K filed with the SEC earlier today. PepGen does not undertake any obligation to publicly update its forward-looking statements as a result of new information, future events, or changes in its expectations.

I will now turn the call over to James McArthur. James?

James McArthur

Thank you, Noel and good afternoon, everyone. Thank you for joining our fourth quarter and full year 2022 investor call. Before we begin, I would like to note that PepGen does not currently intend to hold quarterly calls on a regular basis moving forward. However, with our updated clinical development plan that could lead to a potential accelerated approval for our lead program, PGN-EDO51 or EDO51, we felt the timing to hold this financial results call.